beta-alanine has been researched along with Glaucoma, Suspect in 33 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the intraocular pressure (IOP)-lowering efficacy and safety of netarsudil once daily (QD) and timolol twice daily (BID)." | 9.30 | Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study. ( Bacharach, J; Braswell, P; Heah, T; Khouri, AS; Kopczynski, CC; Lewis, RA; Serle, JB; Usner, DW, 2019) |
| "Adults with open-angle glaucoma or ocular hypertension (unmedicated intraocular pressure [IOP] >20 and <36 mm Hg at 8:00 AM) were randomized to receive once-daily netarsudil/latanoprost FDC, netarsudil 0." | 9.30 | Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial. ( Asrani, S; Heah, T; Kopczynski, CC; Lewis, RA; Robin, AL; Serle, JB; Usner, DW, 2019) |
| " In this study, we conducted a systematic literature review and meta-analysis to summarize and synthesize the available evidence on the efficacy and safety of fixed-dose combination (FDC) therapy with netarsudil/latanoprost in patients with glaucoma." | 9.22 | Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis. ( Ahn, HS; Chang, DJ; Chang, J; Kang, HY; Lee, H; Lee, JW; Suh, JK, 2022) |
| " The objective of this 28-day study was to evaluate the ocular hypotensive efficacy and safety of AR-13324 ophthalmic solution compared with a positive control, latanoprost ophthalmic solution, in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT)." | 9.20 | Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. ( Bacharach, J; Dubiner, HB; Kopczynski, CC; Levy, B; Novack, GD, 2015) |
| "New open-angle glaucoma (OAG) and ocular hypertension (OHT) therapies that reduce treatment burden and improve outcomes relative to currently available agents are needed." | 6.94 | Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2. ( Asrani, S; Bacharach, J; Heah, T; Holland, E; Kopczynski, CC; Lewis, RA; McKee, H; Sheng, H, 2020) |
| " The most frequent adverse event was conjunctival hyperemia, the incidence of which ranged from 50% (126/251, ROCKET-2) to 53% (108/203, ROCKET-1) for netarsudil q." | 6.87 | Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). ( Heah, T; Katz, LJ; Kopczynski, CC; McLaurin, E; Novack, GD; Ramirez-Davis, N; Serle, JB; Usner, DW, 2018) |
| "Initial treatment of glaucoma commonly involves using anti-glaucoma medications either as monotherapy or combination therapy." | 6.66 | New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost. ( Mehran, NA; Razeghinejad, R; Sinha, S, 2020) |
| "02% resulted in intraocular pressure (IOP) reduction that was noninferior to twice-daily timolol 0." | 5.34 | Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension. ( Fechtner, RD; Heah, T; Kim, T; Kopczynski, CC; Lewis, RA; McKee, H; Myers, JS; Sheng, H; Singh, IP; Usner, DW, 2020) |
| "To compare the intraocular pressure (IOP)-lowering efficacy and safety of netarsudil once daily (QD) and timolol twice daily (BID)." | 5.30 | Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study. ( Bacharach, J; Braswell, P; Heah, T; Khouri, AS; Kopczynski, CC; Lewis, RA; Serle, JB; Usner, DW, 2019) |
| "Adults with open-angle glaucoma or ocular hypertension (unmedicated intraocular pressure [IOP] >20 and <36 mm Hg at 8:00 AM) were randomized to receive once-daily netarsudil/latanoprost FDC, netarsudil 0." | 5.30 | Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial. ( Asrani, S; Heah, T; Kopczynski, CC; Lewis, RA; Robin, AL; Serle, JB; Usner, DW, 2019) |
| " In this study, we conducted a systematic literature review and meta-analysis to summarize and synthesize the available evidence on the efficacy and safety of fixed-dose combination (FDC) therapy with netarsudil/latanoprost in patients with glaucoma." | 5.22 | Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis. ( Ahn, HS; Chang, DJ; Chang, J; Kang, HY; Lee, H; Lee, JW; Suh, JK, 2022) |
| " The objective of this 28-day study was to evaluate the ocular hypotensive efficacy and safety of AR-13324 ophthalmic solution compared with a positive control, latanoprost ophthalmic solution, in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT)." | 5.20 | Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure. ( Bacharach, J; Dubiner, HB; Kopczynski, CC; Levy, B; Novack, GD, 2015) |
| "Pharmacotherapies for POAG or ocular hypertension (OHT) commonly lower IOP by increasing uveoscleral outflow or decreasing aqueous humor production." | 3.01 | Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study. ( Challa, P; Gupta, D; Heah, T; Kazemi, A; Kopczynski, C; Liu, KC; Lopez, J; McKee, H; Sit, AJ, 2021) |
| "04% dosed QD (P." | 3.01 | Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension. ( Araie, M; Aso, K; Hollander, DA; Kanemoto, K; Kopczynski, C; Kothapalli, K; Senchyna, M; Sugiyama, K, 2021) |
| "New open-angle glaucoma (OAG) and ocular hypertension (OHT) therapies that reduce treatment burden and improve outcomes relative to currently available agents are needed." | 2.94 | Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2. ( Asrani, S; Bacharach, J; Heah, T; Holland, E; Kopczynski, CC; Lewis, RA; McKee, H; Sheng, H, 2020) |
| " The most frequently reported adverse events (AEs) were ocular, with the most frequent ocular AE being conjunctival hyperemia, with an incidence of 61%, 66%, and 14%, respectively." | 2.90 | Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2). ( Heah, T; Kahook, MY; Kim, T; Kopczynski, CC; Mah, FS; Novack, GD; Raizman, MB; Ramirez-Davis, N; Serle, JB; Usner, DW, 2019) |
| " The most frequent adverse event was conjunctival hyperemia, the incidence of which ranged from 50% (126/251, ROCKET-2) to 53% (108/203, ROCKET-1) for netarsudil q." | 2.87 | Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2). ( Heah, T; Katz, LJ; Kopczynski, CC; McLaurin, E; Novack, GD; Ramirez-Davis, N; Serle, JB; Usner, DW, 2018) |
| "Elevated intraocular pressure is a prime risk factor for blindness in the elderly." | 2.72 | Netarsudil: A new ophthalmic drug in the treatment of chronic primary open angle glaucoma and ocular hypertension. ( Batra, M; Dhanawat, M; Gupta, S; Morsy, MA; Nair, AB; Sandal, S, 2021) |
| "Initial treatment of glaucoma commonly involves using anti-glaucoma medications either as monotherapy or combination therapy." | 2.66 | New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost. ( Mehran, NA; Razeghinejad, R; Sinha, S, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (30.30) | 24.3611 |
| 2020's | 23 (69.70) | 2.80 |
| Authors | Studies |
|---|---|
| Shiuey, EJ | 1 |
| Mehran, NA | 2 |
| Ustaoglu, M | 1 |
| Zhang, Q | 1 |
| Razeghinejad, R | 3 |
| Shukla, AG | 1 |
| Kolomeyer, NN | 2 |
| Myers, JS | 3 |
| Lee, D | 2 |
| Chen, YH | 1 |
| Lin, WY | 1 |
| Huang, YC | 1 |
| Ho, WY | 1 |
| Fu, CW | 1 |
| Tu, CM | 1 |
| Hwang, CS | 1 |
| Hung, CL | 1 |
| Lin, MC | 1 |
| Cheng, F | 1 |
| Wang, YJ | 1 |
| Chen, CH | 1 |
| Chou, SH | 1 |
| She, MP | 1 |
| Yang, CY | 1 |
| Cheng, HL | 1 |
| Liu, CP | 1 |
| Lu, DW | 1 |
| Lyons, LJ | 1 |
| Wu, KY | 1 |
| Baratz, KH | 1 |
| Sit, AJ | 2 |
| Bronner, AW | 1 |
| Goergen, NS | 1 |
| Gagrani, M | 1 |
| Gulati, V | 1 |
| Ghate, D | 1 |
| Lee, JW | 1 |
| Ahn, HS | 1 |
| Chang, J | 1 |
| Kang, HY | 1 |
| Chang, DJ | 1 |
| Suh, JK | 1 |
| Lee, H | 1 |
| Rivera, SS | 1 |
| Radunzel, N | 1 |
| Boese, EA | 1 |
| Bonardi, A | 1 |
| Supuran, CT | 1 |
| Radell, JE | 1 |
| Serle, JB | 5 |
| Sinha, S | 2 |
| Wisely, CE | 1 |
| Sheng, H | 3 |
| Heah, T | 9 |
| Kim, T | 3 |
| Asrani, S | 2 |
| Bacharach, J | 3 |
| Holland, E | 1 |
| McKee, H | 3 |
| Lewis, RA | 5 |
| Kopczynski, CC | 9 |
| Moumneh, K | 1 |
| Sheybani, A | 1 |
| Fellman, RL | 1 |
| Godfrey, DG | 1 |
| Grover, DS | 1 |
| Singh, IP | 1 |
| Fechtner, RD | 1 |
| Usner, DW | 6 |
| Price, MO | 1 |
| Feng, MT | 1 |
| Price, FW | 1 |
| Gonzalez, LE | 1 |
| Boylan, PM | 1 |
| Gupta, D | 1 |
| Kazemi, A | 1 |
| Challa, P | 2 |
| Liu, KC | 1 |
| Lopez, J | 1 |
| Kopczynski, C | 3 |
| Araie, M | 1 |
| Sugiyama, K | 1 |
| Aso, K | 1 |
| Kanemoto, K | 1 |
| Kothapalli, K | 1 |
| Senchyna, M | 1 |
| Hollander, DA | 1 |
| Mehta, AA | 1 |
| Kanu, LN | 1 |
| Sood-Mendiratta, S | 1 |
| Quinones, R | 1 |
| Hawkins, A | 1 |
| Lehrer, RA | 1 |
| Malhotra, K | 1 |
| Papas, R | 1 |
| Hillman, D | 1 |
| Wilensky, JT | 1 |
| Aref, AA | 1 |
| Vajaranant, TS | 1 |
| Edward, DP | 1 |
| Zaman, F | 1 |
| Gieser, SC | 1 |
| Schwartz, GF | 1 |
| Swan, C | 1 |
| Williams, JM | 1 |
| Li, G | 1 |
| Lee, C | 1 |
| Read, AT | 1 |
| Wang, K | 1 |
| Ha, J | 1 |
| Kuhn, M | 1 |
| Navarro, I | 1 |
| Cui, J | 1 |
| Young, K | 1 |
| Gorijavolu, R | 1 |
| Sulchek, T | 1 |
| Farsiu, S | 1 |
| Samples, J | 1 |
| Ethier, CR | 1 |
| Stamer, WD | 1 |
| Batra, M | 1 |
| Gupta, S | 1 |
| Nair, AB | 1 |
| Dhanawat, M | 1 |
| Sandal, S | 1 |
| Morsy, MA | 1 |
| Kim, HM | 1 |
| Tran, AQ | 1 |
| Yang, C | 1 |
| Dagi Glass, LR | 1 |
| Leary, KA | 1 |
| Steibel, JP | 1 |
| Harman, CD | 1 |
| Anderson, AL | 1 |
| Komáromy, AM | 1 |
| Katz, LJ | 1 |
| McLaurin, E | 1 |
| Ramirez-Davis, N | 2 |
| Novack, GD | 4 |
| Tanna, AP | 1 |
| Johnson, M | 1 |
| Kahook, MY | 1 |
| Mah, FS | 1 |
| Raizman, MB | 1 |
| Khouri, AS | 1 |
| Braswell, P | 1 |
| Robin, AL | 1 |
| Dubiner, HB | 1 |
| Levy, B | 2 |
| Ramirez, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Double-masked, Randomized, Multi-center, Active Controlled, Parallel-group, 3-month Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution Compared to AR-13324 Ophthalmic Solution 0.02% and Latanoprost Ophth[NCT02674854] | Phase 3 | 750 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| A Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group 12-month Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution Compared to AR-13324 Ophthalmic Solution, 0.02% and Latanoprost Opht[NCT02558400] | Phase 3 | 718 participants (Actual) | Interventional | 2015-09-18 | Completed | ||
| Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Primary Rhegmatogenous Detachments and Retinal Detachment Due to Proliferative Vitreoretinopathy or Open-Globe Injury: A Phase I/II Clinical Trial[NCT06033703] | Phase 1/Phase 2 | 48 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| Randomized, Double-masked, Placebo-controlled Evaluation of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation[NCT03248037] | Phase 3 | 120 participants (Actual) | Interventional | 2017-09-05 | Completed | ||
| A Prospective, Double-masked, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Assessing the Safety, Ocular Hypotensive Efficacy and Optimum Dose Concentration to be Used Clinically of Netarsudil Ophthalmic Solution in Subjects With Open-[NCT03844945] | Phase 2 | 215 participants (Actual) | Interventional | 2019-03-19 | Completed | ||
| A Multicenter, Open-label Study of Rhopressa® (Netarsudil Ophthalmic Solution) 0.02% for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting[NCT03808688] | Phase 4 | 261 participants (Actual) | Interventional | 2018-12-27 | Completed | ||
| A Double-masked, Randomized, Controlled Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution, 0.01% and PG324 Ophthalmic Solution, 0.02%, Compared to AR-13324 Ophthalmic Solution, 0.02% and Latanoprost Ophthalmic Solutio[NCT02057575] | Phase 2 | 298 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean intraocular pressure(IOP) at 08:00, 10:00 and 16:00 hours, at Day 15, Day 43 and Day 90, as measured by Goldmann applanation tonometry. (NCT02674854)
Timeframe: 3 months
| Intervention | mmHg (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1, 0800 hours | Day 1, 1000 hours | Day 1, 1600 hours | Day 15, 0800 hours | Day 15, 1000 hours | Day 15, 1600 hours | Day 43, 0800 hours | Day 43, 1000 hours | Day 43, 1600 hours | Day 90, 0800 hours | Day 90, 1000 hours | Day 90, 1600 hours | |
| Latanoprost Ophthalmic Solution 0.005% | 24.75 | 23.23 | 22.59 | 18.10 | 17.61 | 17.08 | 17.93 | 17.35 | 17.09 | 17.98 | 17.48 | 17.14 |
| Netarsudil (AR-13324) Ophthalmic Solution 0.02% | 24.66 | 23.40 | 22.76 | 19.35 | 17.99 | 17.53 | 19.52 | 18.40 | 17.95 | 19.72 | 18.30 | 17.94 |
| PG324 Ophthalmic Solution | 24.69 | 23.33 | 22.37 | 16.06 | 15.31 | 15.16 | 16.43 | 15.54 | 15.45 | 16.45 | 15.58 | 15.52 |
Exposure to study medication in days for all treatment groups (NCT02558400)
Timeframe: 12 months
| Intervention | days (Mean) |
|---|---|
| PG324 Ophthalmic Solution 0.02%/0.005% | 275.7 |
| AR-13324 Ophthalmic Solution 0.02% | 266.2 |
| Latanoprost Ophthalmic Solution 0.005% | 330.4 |
The primary efficacy variable was mean IOP at 08:00, 10:00 and 16:00 hours at Day 15, Day 43 and Day 90, as measured by Goldmann applanation tonometry. Secondary analysis were conducted as a part of safety measurements to month 12 on treatment. (NCT02558400)
Timeframe: Primary efficacy endpoint measured for 3 months (data collected at 08:00, 10:00 and 16:00 hours at Day 15, Day 43 and Day 90)
| Intervention | mmHg (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1, 0800 hours | Day 1, 1000 hours | Day 1, 1600 hours | Day 15, 0800 hours | Day 15, 1000 hours | Day 15, 1600 hours | Day 43, 0800 hours | Day 43, 1000 hours | Day 43, 1600 hours | Day 90, 0800 hours | Day 90, 1000 hours | Day 90, 1600 hours | |
| AR-13324 Ophthalmic Solution 0.02% | 24.81 | 23.45 | 22.63 | 18.66 | 17.78 | 17.25 | 19.06 | 17.92 | 17.54 | 19.04 | 17.96 | 17.30 |
| Latanoprost Ophthalmic Solution 0.005% | 24.59 | 23.43 | 23.43 | 17.74 | 17.36 | 17.11 | 17.58 | 17.06 | 16.97 | 17.53 | 16.88 | 16.67 |
| PG324 Ophthalmic Solution | 24.84 | 23.72 | 22.59 | 15.68 | 14.93 | 14.83 | 16.04 | 15.39 | 15.43 | 16.37 | 15.41 | 15.49 |
Intraocular pressure measurement exceeding 24 mm Hg or more than 10 mm Hg greater than the pre-randomization reading. (NCT03248037)
Timeframe: from date of randomization until the date of first documented intraocular pressure elevation exceeding defined threshold up to 9 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Netarsudil | 11 |
| Placebo | 18 |
Mean diurnal IOP within a treatment by Goldman Applanation Tonometry (NCT03844945)
Timeframe: 29 Days
| Intervention | mmHg (Mean) | |||
|---|---|---|---|---|
| Day 1 | Day 8 | Day 15 | Day 29 | |
| Netarsudil Ophthalmic Solution 0.01% | 20.5 | 16.2 | 15.9 | 16.3 |
| Netarsudil Ophthalmic Solution 0.02% | 20.3 | 15.9 | 15.6 | 15.4 |
| Netarsudil Ophthalmic Solution 0.04% | 20.8 | 15.7 | 15.7 | 16.2 |
| Netarsudil Ophthalmic Solution Placebo | 21.1 | 19.8 | 19.3 | 19.3 |
"Percent Change from Baseline IOP at Week 12, as measured by Goldmann applanation tonometry.~Prostaglandin analog (PGA). Fixed dose combination (FDC)." (NCT03808688)
Timeframe: 12 weeks
| Intervention | percent change (Mean) |
|---|---|
| Netarsudil Ophth Sol 0.02% Monotherapy - Tx Naïve At Baseline | -16.9 |
| Netarsudil Ophth Sol 0.02% Monotherapy - Replaced 1 Agent | -2.3 |
| Netarsudil Ophth Sol 0.02% Monotherapy - Replaced 2 Agents | 0.2 |
| Netarsudil Ophth Sol 0.02% Concomitant Therapy | -17.0 |
The primary efficacy endpoint was the mean diurnal IOP across subjects within treatment group at Day 29. (NCT02057575)
Timeframe: Study treatment was administered for 28 days, and outcome measures collected on Day 29
| Intervention | mmHg (Mean) | |
|---|---|---|
| Day 1, Diurnal Mean | Day 29, Diurnal Mean | |
| Latanoprost Ophthalmic Solution | 25.99 | 18.44 |
| Netarsudil (AR-13324) Ophthalmic Solution | 25.35 | 19.13 |
| PG324 Ophthalmic Solution 0.01% | 25.11 | 17.33 |
| PG324 Ophthalmic Solution 0.02% | 25.12 | 16.52 |
8 reviews available for beta-alanine and Glaucoma, Suspect
| Article | Year |
|---|---|
Honeycomb Epithelial Edema Associated With Rho Kinase Inhibition: A Case Series and Review of the Literature.
Topics: Benzoates; beta-Alanine; Corneal Edema; Epithelium, Corneal; Humans; Intraocular Pressure; Ocular Hy | 2022 |
Comparison of Netarsudil/Latanoprost Therapy with Latanoprost Monotherapy for Lowering Intraocular Pressure: A Systematic Review and Meta-analysis.
Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocula | 2022 |
Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension.
Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Drug Combinations; Female; Glaucoma; Humans; Intra | 2020 |
New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost.
Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocula | 2020 |
Netarsudil for the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Literature Review.
Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Glaucoma, Open-Angle; Humans; Intraocular Pressure | 2021 |
Netarsudil: A new ophthalmic drug in the treatment of chronic primary open angle glaucoma and ocular hypertension.
Topics: Aged; Antihypertensive Agents; Benzoates; beta-Alanine; Glaucoma, Open-Angle; Humans; Intraocular Pr | 2021 |
Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension.
Topics: Antihypertensive Agents; Aqueous Humor; Benzoates; beta-Alanine; Glaucoma, Open-Angle; Humans; Intra | 2018 |
Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension.
Topics: Administration, Ophthalmic; Animals; Benzoates; beta-Alanine; Drug Interactions; Eye; Glaucoma, Open | 2018 |
13 trials available for beta-alanine and Glaucoma, Suspect
| Article | Year |
|---|---|
Effects of Netarsudil and Latanoprost Alone and in Fixed Combination on Corneal Endothelium and Corneal Thickness: Post-Hoc Analysis of MERCURY-2.
Topics: Aged; Benzoates; beta-Alanine; Double-Blind Method; Drug Combinations; Endothelium, Corneal; Female; | 2020 |
Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
Topics: Aged; Antihypertensive Agents; Benzoates; beta-Alanine; Female; Glaucoma, Open-Angle; Humans; Intrao | 2020 |
Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
Topics: Aged; Antihypertensive Agents; Benzoates; beta-Alanine; Female; Glaucoma, Open-Angle; Humans; Intrao | 2020 |
Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
Topics: Aged; Antihypertensive Agents; Benzoates; beta-Alanine; Female; Glaucoma, Open-Angle; Humans; Intrao | 2020 |
Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
Topics: Aged; Antihypertensive Agents; Benzoates; beta-Alanine; Female; Glaucoma, Open-Angle; Humans; Intrao | 2020 |
Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension.
Topics: Administration, Ophthalmic; Adult; Aged; Antihypertensive Agents; Benzoates; beta-Alanine; Double-Bl | 2020 |
Randomized, Double-Masked Trial of Netarsudil 0.02% Ophthalmic Solution for Prevention of Corticosteroid-Induced Ocular Hypertension.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; beta-Alanine; Double-Blind Method; Female; Follow-Up Stud | 2021 |
Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study.
Topics: Administration, Ophthalmic; Adult; Aged; Aqueous Humor; Benzoates; beta-Alanine; Double-Blind Method | 2021 |
Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension.
Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Double-Blind Method; Glaucoma, Open-Angle; Humans; | 2021 |
A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting.
Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Glaucoma, Open-Angle; Humans; Intraocular Pressure | 2021 |
Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzoates; beta-Alanine; Child; | 2018 |
Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2).
Topics: Administration, Ophthalmic; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Benzo | 2019 |
Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzoates; beta-Alanine; Dose-Response Rela | 2019 |
Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial.
Topics: Administration, Ophthalmic; Aged; Antihypertensive Agents; Benzoates; beta-Alanine; Double-Blind Met | 2019 |
Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzoates; beta-Al | 2015 |
Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzoates; beta-Alanine; Corneal Pachymetry | 2016 |
12 other studies available for beta-alanine and Glaucoma, Suspect
| Article | Year |
|---|---|
The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes.
Topics: Aged; Aged, 80 and over; Benzoates; beta-Alanine; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocula | 2022 |
The Intraocular Pressure Lowering Effect of a Dual Kinase Inhibitor (ITRI-E-(S)4046) in Ocular Hypertensive Animal Models.
Topics: Animals; Benzoates; beta-Alanine; Calcium-Binding Proteins; Disease Models, Animal; Humans; Intraocu | 2021 |
Case Report: Topical Netarsudil in the Treatment of a Neurotrophic Corneal Ulcer.
Topics: Benzoates; beta-Alanine; Corneal Ulcer; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Ocular H | 2022 |
Pragmatic adjunctive usage of netarsudil: A retrospective chart review from a tertiary care center.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzoates; beta-Alanine; Female; Glaucoma; Glaucom | 2022 |
Symptomatic Netarsudil-Induced Verticillata.
Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Glaucoma, Open-Angle; Humans; Intraocular Pressure | 2023 |
Treatment of glaucoma and ocular hypertension using rho kinase inhibitors: patent evaluation of US2018244666 and US2018256595.
Topics: Benzoates; beta-Alanine; Glaucoma; Humans; Intraocular Pressure; Isoquinolines; Ocular Hypertension; | 2019 |
Netarsudil/latanoprost fixed-dose combination for the treatment of open-angle glaucoma or ocular hypertension.
Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Drug Approval; Drug Therapy, Combination; Glaucoma | 2019 |
Reticular Corneal Edema or Corneal Honeycombing in Eyes Treated With Netarsudil: A Case Series.
Topics: Aged; Antihypertensive Agents; Benzoates; beta-Alanine; Corneal Edema; Female; Glaucoma, Open-Angle; | 2020 |
Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma.
Topics: Antihypertensive Agents; Benzoates; beta-Alanine; Cohort Studies; Glaucoma; Glaucoma, Open-Angle; Hu | 2022 |
Anti-fibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antihypertensive Agents; Benzoates; beta-Alanin | 2021 |
Netarsudil-related Eyelid Wound Dehiscence.
Topics: Aged, 80 and over; Antihypertensive Agents; Benzoates; beta-Alanine; Eyelids; Glaucoma, Open-Angle; | 2021 |
Safety and efficacy of topically administered netarsudil-latanoprost fixed dose combination (FDC; Rocklatan™) in normal and glaucomatous dogs with ADAMTS10-open-angle glaucoma (ADAMTS10-OAG).
Topics: Animals; Antihypertensive Agents; Benzoates; beta-Alanine; Dog Diseases; Dogs; Double-Blind Method; | 2021 |